Skip to main content
Top
Published in: Clinical and Translational Oncology 1/2019

Open Access 01-01-2019 | Clinical Guides in Oncology

SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018)

Authors: A. Carmona-Bayonas, P. Jimenez-Fonseca, E. M. de Castro, E. Mata, M. Biosca, A. Custodio, J. Espinosa, E. G. Vázquez, F. Henao, F. Ayala de la Peña

Published in: Clinical and Translational Oncology | Issue 1/2019

Login to get access

Abstract

Febrile neutropenia (FN) is a common dose-limiting toxicity of chemotherapy, with a profound impact on the evolution of patients with cancer, due to the potential development of serious complications, mortality, delays, and decrease in treatment intensity. This article seeks to present an updated clinical guideline, with recommendations regarding the diagnosis, prevention, and treatment of febrile neutropenia in adults with solid tumors. The aspects covered include how to properly approach the risk of microbial resistances, epidemiological aspects, considerations about the initial empirical approach adapted to the risk, special situations, and prevention of complications. A decision-making algorithm is included for use in the emergency department based on a new, validated tool, the Clinical Index of Stable Febrile Neutropenia, which can be used in patients with solid tumors who appear stable in the initial phase of neutropenic infections, and can help detect those at high risk for complications in whom early discharge must be avoided.
Literature
1.
go back to reference Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18(16):3038–51.CrossRef Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18(16):3038–51.CrossRef
2.
go back to reference Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(5):v111–8.CrossRef Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(5):v111–8.CrossRef
3.
go back to reference Weycker D, Barron R, Kartashov A, Legg J, Lyman GH. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. J Oncol Pharm Pract. 2014;20(3):190–8.CrossRef Weycker D, Barron R, Kartashov A, Legg J, Lyman GH. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. J Oncol Pharm Pract. 2014;20(3):190–8.CrossRef
4.
go back to reference Taplitz RA, Kennedy EB, Flowers CR. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline update summary. J Oncol Pract. 2018;14:250–5.CrossRef Taplitz RA, Kennedy EB, Flowers CR. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline update summary. J Oncol Pract. 2018;14:250–5.CrossRef
5.
go back to reference McCune JS, Sullivan SD, Blough DK, Clarke L, McDermott C, Malin J, et al. Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy. Pharmacotherapy. 2012;32(1):7–19.CrossRef McCune JS, Sullivan SD, Blough DK, Clarke L, McDermott C, Malin J, et al. Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy. Pharmacotherapy. 2012;32(1):7–19.CrossRef
6.
go back to reference Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258–66.CrossRef Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258–66.CrossRef
7.
go back to reference Mayordomo JI, López A, Viñolas N, Castellanos J, Pernas S, Domingo Alonso J, et al. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain. Curr Med Res Opin. 2009;25(10):2533–42.CrossRef Mayordomo JI, López A, Viñolas N, Castellanos J, Pernas S, Domingo Alonso J, et al. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain. Curr Med Res Opin. 2009;25(10):2533–42.CrossRef
8.
go back to reference Schilling MB, Parks C, Deeter RG. Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: a retrospective study. Exp Ther Med. 2011;2(5):859–66.CrossRef Schilling MB, Parks C, Deeter RG. Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: a retrospective study. Exp Ther Med. 2011;2(5):859–66.CrossRef
9.
go back to reference Pettengell R, Schwenkglenks M, Leonard R, Bosly A, Paridaens R, Constenla M, et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer. 2008;16(11):1299–309.CrossRef Pettengell R, Schwenkglenks M, Leonard R, Bosly A, Paridaens R, Constenla M, et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer. 2008;16(11):1299–309.CrossRef
10.
go back to reference Lyman GH, Michels SL, Reynolds MW, Barron R, Tomic KS, Yu J. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer. 2010;116(23):5555–63.CrossRef Lyman GH, Michels SL, Reynolds MW, Barron R, Tomic KS, Yu J. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer. 2010;116(23):5555–63.CrossRef
11.
go back to reference Aapro MS, Bohlius J, Cameron DA, Lago LD, Donnelly JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8–32.CrossRef Aapro MS, Bohlius J, Cameron DA, Lago LD, Donnelly JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8–32.CrossRef
12.
go back to reference Balducci L, Al-Halawani H, Charu V, Tam J, Shahin S, Dreiling L, et al. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist. 2007;12(12):1416–24.CrossRef Balducci L, Al-Halawani H, Charu V, Tam J, Shahin S, Dreiling L, et al. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist. 2007;12(12):1416–24.CrossRef
13.
go back to reference von Minckwitz G, Kümmel S, du Bois A, Eiermann W, Eidtmann H, Gerber B, et al. Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol. 2008;19(2):292–8.CrossRef von Minckwitz G, Kümmel S, du Bois A, Eiermann W, Eidtmann H, Gerber B, et al. Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol. 2008;19(2):292–8.CrossRef
14.
go back to reference Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela J, Antonio M, Font C, Biosca M, et al. Performance of the clinical index of stable febrile neutropenia (CISNE) in different types of infections and tumors. Clin Transl Oncol. 2016;19(3):1–10. Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela J, Antonio M, Font C, Biosca M, et al. Performance of the clinical index of stable febrile neutropenia (CISNE) in different types of infections and tumors. Clin Transl Oncol. 2016;19(3):1–10.
15.
go back to reference Carmona-Bayonas A, Fonseca PJ, Font C, Martínez-García J, Torrella F, Urrego E, et al. Bacteremia in adult cancer patients with apparently stable febrile neutropenia: data from a cohort of 692 consecutive episodes from a single institution. J Community Support Oncol. 2014;12(9):312–20.CrossRef Carmona-Bayonas A, Fonseca PJ, Font C, Martínez-García J, Torrella F, Urrego E, et al. Bacteremia in adult cancer patients with apparently stable febrile neutropenia: data from a cohort of 692 consecutive episodes from a single institution. J Community Support Oncol. 2014;12(9):312–20.CrossRef
16.
go back to reference Viscoli C. Management of infection in cancer patients: studies of the EORTC International Antimicrobial Therapy Group (IATG). Eur J Cancer. 2002;38:82–7.CrossRef Viscoli C. Management of infection in cancer patients: studies of the EORTC International Antimicrobial Therapy Group (IATG). Eur J Cancer. 2002;38:82–7.CrossRef
17.
go back to reference Trecarichi EM, Tumbarello M. Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact. Curr Opin Infect Dis. 2014;27(2):200–10.CrossRef Trecarichi EM, Tumbarello M. Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact. Curr Opin Infect Dis. 2014;27(2):200–10.CrossRef
18.
go back to reference Ben-Ami R, Rodríguez-Baño J, Arslan H, Pitout JDD, Quentin C, Calbo ES, et al. A multinational survey of risk factors for infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin Infect Dis. 2009;49(5):682–90.CrossRef Ben-Ami R, Rodríguez-Baño J, Arslan H, Pitout JDD, Quentin C, Calbo ES, et al. A multinational survey of risk factors for infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin Infect Dis. 2009;49(5):682–90.CrossRef
19.
go back to reference Ram R, Farbman L, Leibovici L, Raanani P, Yeshurun M, Vidal L, et al. Characteristics of initial compared with subsequent bacterial infections among hospitalised haemato-oncological patients. Int J Antimicrob Agents. 2012;40(2):123–6.CrossRef Ram R, Farbman L, Leibovici L, Raanani P, Yeshurun M, Vidal L, et al. Characteristics of initial compared with subsequent bacterial infections among hospitalised haemato-oncological patients. Int J Antimicrob Agents. 2012;40(2):123–6.CrossRef
20.
go back to reference Furuno JP, McGregor JC, Harris AD, Johnson JA, Johnson JK, Langenberg P, et al. Identifying groups at high risk for carriage of antibiotic-resistant bacteria. Arch Intern Med. 2006;166(5):580–5.CrossRef Furuno JP, McGregor JC, Harris AD, Johnson JA, Johnson JK, Langenberg P, et al. Identifying groups at high risk for carriage of antibiotic-resistant bacteria. Arch Intern Med. 2006;166(5):580–5.CrossRef
21.
go back to reference EARS-Net. Antimicrobial resistance surveillance in Europe 2015. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net); 2015. EARS-Net. Antimicrobial resistance surveillance in Europe 2015. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net); 2015.
22.
go back to reference Mensa J, Gatell JM, García-Sánchez JE, Marco E, Letang E, López-Suñé F. Guía de terapéutica antimicrobiana. Barcelona: Antares; 2017. Mensa J, Gatell JM, García-Sánchez JE, Marco E, Letang E, López-Suñé F. Guía de terapéutica antimicrobiana. Barcelona: Antares; 2017.
23.
go back to reference Carmona-Bayonas A, Gómez J, González-Billalabeitia E, Canteras M, Navarrete A, Gonzálvez ML, et al. Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients. Br J Cancer. 2011;105(5):612–7.CrossRef Carmona-Bayonas A, Gómez J, González-Billalabeitia E, Canteras M, Navarrete A, Gonzálvez ML, et al. Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients. Br J Cancer. 2011;105(5):612–7.CrossRef
24.
go back to reference Heussel CP, Kauczor H-U, Ullmann AJ. Pneumonia in neutropenic patients. Eur Radiol. 2004;14(2):256–71.CrossRef Heussel CP, Kauczor H-U, Ullmann AJ. Pneumonia in neutropenic patients. Eur Radiol. 2004;14(2):256–71.CrossRef
25.
go back to reference Carmona-Bayonas A, Gómez J, González-Billalabeitia E, Canteras M, Navarrete A, Gonzálvez ML, et al. Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients. Br J Cancer. 2011;105(5):612.CrossRef Carmona-Bayonas A, Gómez J, González-Billalabeitia E, Canteras M, Navarrete A, Gonzálvez ML, et al. Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients. Br J Cancer. 2011;105(5):612.CrossRef
26.
go back to reference Carmona-Bayonas A, Jiménez-Fonseca P, Echaburu JV, Antonio M, Font C, Biosca M, et al. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the clinical index of stable febrile neutropenia in a prospective cohort of patients from the FINITE study. J Clin Oncol. 2015;33(5):465.CrossRef Carmona-Bayonas A, Jiménez-Fonseca P, Echaburu JV, Antonio M, Font C, Biosca M, et al. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the clinical index of stable febrile neutropenia in a prospective cohort of patients from the FINITE study. J Clin Oncol. 2015;33(5):465.CrossRef
27.
go back to reference Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–10.CrossRef Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–10.CrossRef
28.
go back to reference Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992;101(6):1644–55.CrossRef Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992;101(6):1644–55.CrossRef
29.
go back to reference Fonseca PJ, Carmona-Bayonas A, García IM, Marcos R, Castañón E, Antonio M, et al. A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia. Br J Cancer. 2016;114(11):1191–8.CrossRef Fonseca PJ, Carmona-Bayonas A, García IM, Marcos R, Castañón E, Antonio M, et al. A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia. Br J Cancer. 2016;114(11):1191–8.CrossRef
30.
go back to reference Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103(9):1916–24.CrossRef Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103(9):1916–24.CrossRef
31.
go back to reference Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol. 1992;10(2):316–22.CrossRef Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol. 1992;10(2):316–22.CrossRef
32.
go back to reference Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2013;31(6):794–810.CrossRef Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2013;31(6):794–810.CrossRef
33.
go back to reference Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela Echaburu J, Sánchez Cánovas M, de la Peña AF. The time has come for new models in febrile neutropenia: a practical demonstration of the inadequacy of the MASCC score. Clin Transl Oncol. 2017;19(9):1084–90.CrossRef Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela Echaburu J, Sánchez Cánovas M, de la Peña AF. The time has come for new models in febrile neutropenia: a practical demonstration of the inadequacy of the MASCC score. Clin Transl Oncol. 2017;19(9):1084–90.CrossRef
34.
go back to reference Carmona-Bayonas A, Jiménez-Fonseca P. CISNE or MASCC, which predictor is really the weakest in febrile neutropenia? Eur J Intern Med. 2018;50:e33–4.CrossRef Carmona-Bayonas A, Jiménez-Fonseca P. CISNE or MASCC, which predictor is really the weakest in febrile neutropenia? Eur J Intern Med. 2018;50:e33–4.CrossRef
35.
go back to reference Clark OAC, Lyman GH, Castro AA, Clark LGO, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005;23(18):4198–214.CrossRef Clark OAC, Lyman GH, Castro AA, Clark LGO, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005;23(18):4198–214.CrossRef
36.
go back to reference García-Carbonero R, Mayordomo JI, Tornamira MV, López-Brea M, Rueda A, Guillem V, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst. 2001;93(1):31–8.CrossRef García-Carbonero R, Mayordomo JI, Tornamira MV, López-Brea M, Rueda A, Guillem V, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst. 2001;93(1):31–8.CrossRef
37.
go back to reference Mercier T, Maertens J. Clinical considerations in the early treatment of invasive mould infections and disease. J Antimicrob Chemother. 2017;72(suppl_1):i29–38.CrossRef Mercier T, Maertens J. Clinical considerations in the early treatment of invasive mould infections and disease. J Antimicrob Chemother. 2017;72(suppl_1):i29–38.CrossRef
38.
go back to reference van Dalen EC, Mank A, Leclercq E, Mulder RL, Davies M, Kersten MJ, et al. Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia. Cochrane Database Syst Rev. 2016;4:CD006247.PubMed van Dalen EC, Mank A, Leclercq E, Mulder RL, Davies M, Kersten MJ, et al. Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia. Cochrane Database Syst Rev. 2016;4:CD006247.PubMed
39.
go back to reference Allegranzi B, Pittet D. Role of hand hygiene in healthcare-associated infection prevention. J Hosp Infect. 2009;73(4):305–15.CrossRef Allegranzi B, Pittet D. Role of hand hygiene in healthcare-associated infection prevention. J Hosp Infect. 2009;73(4):305–15.CrossRef
40.
go back to reference Siegel JD, Rhinehart E, Jackson M, Chiarello L. 2007 guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control. 2007;35(10):S65–164.CrossRef Siegel JD, Rhinehart E, Jackson M, Chiarello L. 2007 guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control. 2007;35(10):S65–164.CrossRef
41.
go back to reference Carmona-Bayonas A, Gordo F, Beato C, Castaño Pérez J, Jiménez-Fonseca P, Virizuela Echaburu J, et al. Intensive care in cancer patients in the age of immunotherapy and molecular therapies: commitment of the SEOM-SEMICYUC. Med Intensiva. 2018;42(6):363–9.CrossRef Carmona-Bayonas A, Gordo F, Beato C, Castaño Pérez J, Jiménez-Fonseca P, Virizuela Echaburu J, et al. Intensive care in cancer patients in the age of immunotherapy and molecular therapies: commitment of the SEOM-SEMICYUC. Med Intensiva. 2018;42(6):363–9.CrossRef
43.
go back to reference Virizuela JA, Carratalà J, Aguado JM, Vicente D, Salavert M, Ruiz M, et al. Management of infection and febrile neutropenia in patients with solid cancer. Clin Transl Oncol. 2016;18(6):557–70.CrossRef Virizuela JA, Carratalà J, Aguado JM, Vicente D, Salavert M, Ruiz M, et al. Management of infection and febrile neutropenia in patients with solid cancer. Clin Transl Oncol. 2016;18(6):557–70.CrossRef
44.
go back to reference Lyman GH, Kuderer NM, Crawford J, Wolff DA, Culakova E, Poniewierski MS, et al. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer. 2011;117(9):1917–27.CrossRef Lyman GH, Kuderer NM, Crawford J, Wolff DA, Culakova E, Poniewierski MS, et al. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer. 2011;117(9):1917–27.CrossRef
45.
go back to reference Baden LR, Swaminathan S, Angarone M, Blouin G, Camins BC, Casper C, et al. Prevention and treatment of cancer-related infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2016;14(7):882–913.CrossRef Baden LR, Swaminathan S, Angarone M, Blouin G, Camins BC, Casper C, et al. Prevention and treatment of cancer-related infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2016;14(7):882–913.CrossRef
46.
go back to reference Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187–205.CrossRef Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187–205.CrossRef
47.
go back to reference Mhaskar R, Clark OAC, Lyman G, Botrel TEA, Paladini LM, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev. 2014;10:CD003039. Mhaskar R, Clark OAC, Lyman G, Botrel TEA, Paladini LM, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev. 2014;10:CD003039.
48.
go back to reference Crawford J, Glaspy JA, Stoller RG, Tomita DK, Vincent ME, McGuire BW, et al. Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia. Support Cancer Ther. 2005;3(1):36–46.CrossRef Crawford J, Glaspy JA, Stoller RG, Tomita DK, Vincent ME, McGuire BW, et al. Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia. Support Cancer Ther. 2005;3(1):36–46.CrossRef
49.
go back to reference Person AK, Pettit AC, Sterling TR. Diagnosis and treatment of latent tuberculosis infection: an update. Curr Respir Care Rep. 2013;2(4):199–207.CrossRef Person AK, Pettit AC, Sterling TR. Diagnosis and treatment of latent tuberculosis infection: an update. Curr Respir Care Rep. 2013;2(4):199–207.CrossRef
Metadata
Title
SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018)
Authors
A. Carmona-Bayonas
P. Jimenez-Fonseca
E. M. de Castro
E. Mata
M. Biosca
A. Custodio
J. Espinosa
E. G. Vázquez
F. Henao
F. Ayala de la Peña
Publication date
01-01-2019
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 1/2019
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-018-1983-4

Other articles of this Issue 1/2019

Clinical and Translational Oncology 1/2019 Go to the issue

Acknowledgement to Reviewers

Thanks to reviewers 2018

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine